Moxestrol
| Clinical data | |
|---|---|
| Trade names | Surestryl | 
| Other names | R-2858, RU-2858, NSC-118191; 11β-Methoxy-17α-ethynylestradiol; 11β-MeO-EE 11β-Methoxy-17α-ethynylestra-1,3,5(10)-triene-3,17β-diol | 
| Pregnancy category | 
 | 
| Routes of administration | By mouth | 
| Drug class | Estrogen; Estrogen ether | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | 33% | 
| Protein binding | Minimal | 
| Metabolism | Liver | 
| Elimination half-life | 8.2 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H26O3 | 
| Molar mass | 326.436 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Moxestrol, sold under the brand name Surestryl, is an estrogen medication which has been used in Europe for the treatment of menopausal symptoms and menstrual disorders. It is taken by mouth. In addition to its use as a medication, moxestrol has been used in scientific research as a radioligand of the estrogen receptor.